Lysosome-targeting chimaeras for degradation of extracellular proteins

被引:724
作者
Banik, Steven M. [1 ]
Pedram, Kayvon [1 ]
Wisnovsky, Simon [1 ]
Ahn, Green [1 ]
Riley, Nicholas M. [1 ]
Bertozzi, Carolyn R. [1 ,2 ]
机构
[1] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
[2] Howard Hughes Med Inst, Stanford, CA 94305 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
MANNOSE; 6-PHOSPHATE; COMPUTATIONAL PLATFORM; RECEPTOR; ANTIBODY; CONJUGATION; STRATEGY; AFFINITY; DISEASE;
D O I
10.1038/s41586-020-2545-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein-for example, enzyme inhibition or ligand blocking. However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies. Protein-degradation platforms such as proteolysis-targeting chimaeras (PROTACs)(1,2)and others (for example, dTAGs(3), Trim-Away(4), chaperone-mediated autophagy targeting(5)and SNIPERs(6)) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degradation machinery and are therefore fundamentally limited to proteins that contain cytosolic domains to which ligands can bind and recruit the requisite cellular components. Extracellular and membrane-associated proteins-the products of 40% of all protein-encoding genes(7)-are key agents in cancer, ageing-related diseases and autoimmune disorders(8), and so a general strategy to selectively degrade these proteins has the potential to improve human health. Here we establish the targeted degradation of extracellular and membrane-associated proteins using conjugates that bind both a cell-surface lysosome-shuttling receptor and the extracellular domain of a target protein. These initial lysosome-targeting chimaeras, which we term LYTACs, consist of a small molecule or antibody fused to chemically synthesized glycopeptide ligands that are agonists of the cation-independent mannose-6-phosphate receptor (CI-M6PR). We use LYTACs to develop a CRISPR interference screen that reveals the biochemical pathway for CI-M6PR-mediated cargo internalization in cell lines, and uncover the exocyst complex as a previously unidentified-but essential-component of this pathway. We demonstrate the scope of this platform through the degradation of therapeutically relevant proteins, including apolipoprotein E4, epidermal growth factor receptor, CD71 and programmed death-ligand 1. Our results establish a modular strategy for directing secreted and membrane proteins for lysosomal degradation, with broad implications for biochemical research and for therapeutics. Lysosome-targeting chimaeras-in which a small molecule or antibody is connected to a glycopeptide ligand to form a conjugate that can bind a cell-surface lysosome-shuttling receptor and a protein target-are used to achieve the targeted degradation of extracellular and membrane proteins.
引用
收藏
页码:291 / +
页数:28
相关论文
共 46 条
[1]   AFFINITY CLEAVAGE OF CELL-SURFACE ANTIBODIES USING THE AVIDIN-BIOTIN SYSTEM [J].
ALON, R ;
BAYER, EA ;
WILCHEK, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 165 (01) :127-134
[2]   Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells [J].
Beljaars, L ;
Molema, G ;
Weert, B ;
Bonnema, H ;
Olinga, P ;
Groothuis, GMM ;
Meijer, DKF ;
Poelstra, K .
HEPATOLOGY, 1999, 29 (05) :1486-1493
[3]   Mono- and bivalent ligands bearing mannose 6-phosphate (M6P) surrogates: Targeting the M6P/insulin-like growth factor II receptor [J].
Berkowitz, DB ;
Maiti, G ;
Charette, BD ;
Dreis, CD ;
MacDonald, RG .
ORGANIC LETTERS, 2004, 6 (26) :4921-4924
[4]   The human secretome atlas initiative: Implications in health and disease conditions [J].
Brown, Kristy J. ;
Seol, Haeri ;
Pillai, Dinesh K. ;
Sankoorikal, Binu-John ;
Formolo, Catherine A. ;
Mac, Jenny ;
Edwards, Nathan J. ;
Rose, Mary C. ;
Hathout, Yetrib .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2013, 1834 (11) :2454-2461
[5]   CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity [J].
Burr, Marian L. ;
Sparbier, Christina E. ;
Chan, Yih-Chih ;
Williamson, James C. ;
Woods, Katherine ;
Beavis, Paul A. ;
Lam, Enid Y. N. ;
Henderson, Melissa A. ;
Bell, Charles C. ;
Stolzenburg, Sabine ;
Gilan, Omer ;
Bloor, Stuart ;
Noori, Tahereh ;
Morgens, David W. ;
Bassik, Michael C. ;
Neeson, Paul J. ;
Behren, Andreas ;
Darcy, Phillip K. ;
Dawson, Sarah-Jane ;
Voskoboinik, Ilia ;
Trapani, Joseph A. ;
Cebon, Jonathan ;
Lehner, Paul J. ;
Dawson, Mark A. .
NATURE, 2017, 549 (7670) :101-105
[6]   A Method for the Acute and Rapid Degradation of Endogenous Proteins [J].
Clift, Dean ;
McEwan, William A. ;
Labzin, Larisa I. ;
Konieczny, Vera ;
Mogessie, Binyam ;
James, Leo C. ;
Schuh, Melina .
CELL, 2017, 171 (07) :1692-+
[7]   A shortcut to the lysosome: The mannose-6-phosphate-independent pathway [J].
Coutinho, Maria Francisca ;
Prata, Maria Joao ;
Alves, Sandra .
MOLECULAR GENETICS AND METABOLISM, 2012, 107 (03) :257-266
[8]   Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ [J].
Cox, Juergen ;
Hein, Marco Y. ;
Luber, Christian A. ;
Paron, Igor ;
Nagaraj, Nagarjuna ;
Mann, Matthias .
MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (09) :2513-2526
[9]   Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment [J].
Cox, Juergen ;
Neuhauser, Nadin ;
Michalski, Annette ;
Scheltema, Richard A. ;
Olsen, Jesper V. ;
Mann, Matthias .
JOURNAL OF PROTEOME RESEARCH, 2011, 10 (04) :1794-1805
[10]   Controlled Synthesis of End-Functionalized Mannose-6-phosphate Glycopolypeptides for Lysosome Targeting [J].
Das, Soumen ;
Parekh, Nimisha ;
Mondal, Basudeb ;
Sen Gupta, Sayam .
ACS MACRO LETTERS, 2016, 5 (07) :809-813